Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Labauge

Showing results (181-190 of 288) with videos related to

Pageof 29
Sort By:
Neurology(R) Neuroimmunology & Neuroinflammation|June 6, 2020
Two neurologic facets of CTLA4-related haploinsufficiencyXavier Ayrignac, Radjiv Goulabchand, Eric Jeziorski, et al.
Alzheimer'S Research & Therapy|October 3, 2020
Cerebrospinal fluid A beta 1-40 peptides increase in Alzheimer's disease and are highly correlated with phospho-tau in control individualsSylvain Lehmann, Julien Dumurgier, Xavier Ayrignac, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 3, 2016
MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled studyAyman Tourbah, Christine Lebrun-Frenay, Gilles Edan, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 1, 2022
Pregnancy and post-partum in patients with myelin-oligodendrocyte glycoprotein antibody-associated diseaseClarisse Carra-Dallière, Fabien Rollot, Romain Deschamps, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|November 22, 2022
Secondary Progressive Multiple Sclerosis: A Review of Clinical Characteristics, Definition, Prognostic Tools, and Disease-Modifying TherapiesTjalf Ziemssen, Virender Bhan, Jeremy Chataway, et al.
Neurology and Therapy|December 23, 2022
The Place of Immune Reconstitution Therapy in the Management of Relapsing Multiple Sclerosis in France: An Expert ConsensusJerome De Sèze, Laurent Suchet, Claude Mekies, et al.
Multiple Sclerosis and Related Disorders|August 5, 2021
MSCopilot: New smartphone-based digital biomarkers correlate with Expanded Disability Status Scale scores in people with Multiple SclerosisIan-Christopher Tanoh, Elisabeth Maillart, Pierre Labauge, et al.
European Journal of Neurology|October 26, 2020
Outcomes of coronavirus disease 2019 in patients with neuromyelitis optica and associated disordersCéline Louapre, Elisabeth Maillart, Caroline Papeix, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|June 16, 2017
Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcomeElisabeth Maillart, Jean-Sebastien Vidal, David Brassat, et al.
Plos One|January 4, 2017
Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple SclerosisBruno Brochet, Mathilde S A Deloire, Paul Perez, et al.
Pageof 29

Showing results (181-190 of 288) with videos related to

Sort By:
Pageof 29
Neurology(R) Neuroimmunology & Neuroinflammation|June 6, 2020
Two neurologic facets of CTLA4-related haploinsufficiencyXavier Ayrignac, Radjiv Goulabchand, Eric Jeziorski, et al.
Alzheimer'S Research & Therapy|October 3, 2020
Cerebrospinal fluid A beta 1-40 peptides increase in Alzheimer's disease and are highly correlated with phospho-tau in control individualsSylvain Lehmann, Julien Dumurgier, Xavier Ayrignac, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 3, 2016
MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled studyAyman Tourbah, Christine Lebrun-Frenay, Gilles Edan, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 1, 2022
Pregnancy and post-partum in patients with myelin-oligodendrocyte glycoprotein antibody-associated diseaseClarisse Carra-Dallière, Fabien Rollot, Romain Deschamps, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|November 22, 2022
Secondary Progressive Multiple Sclerosis: A Review of Clinical Characteristics, Definition, Prognostic Tools, and Disease-Modifying TherapiesTjalf Ziemssen, Virender Bhan, Jeremy Chataway, et al.
Neurology and Therapy|December 23, 2022
The Place of Immune Reconstitution Therapy in the Management of Relapsing Multiple Sclerosis in France: An Expert ConsensusJerome De Sèze, Laurent Suchet, Claude Mekies, et al.
Multiple Sclerosis and Related Disorders|August 5, 2021
MSCopilot: New smartphone-based digital biomarkers correlate with Expanded Disability Status Scale scores in people with Multiple SclerosisIan-Christopher Tanoh, Elisabeth Maillart, Pierre Labauge, et al.
European Journal of Neurology|October 26, 2020
Outcomes of coronavirus disease 2019 in patients with neuromyelitis optica and associated disordersCéline Louapre, Elisabeth Maillart, Caroline Papeix, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|June 16, 2017
Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcomeElisabeth Maillart, Jean-Sebastien Vidal, David Brassat, et al.
Plos One|January 4, 2017
Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple SclerosisBruno Brochet, Mathilde S A Deloire, Paul Perez, et al.
Pageof 29